Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06291376 · ClinicalTrials.gov registry record · Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

A Phase 3 study of Immunoglobulin A Nephropathy and IgAN, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
510
Enrollment target
20
Study locations

NCT06291376 is a Phase 3 study of Immunoglobulin A Nephropathy and IgAN that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 510 participants, above the 265-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06291376, a Phase 3 study of Immunoglobulin A Nephropathy and IgAN, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
510 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Conditions Studied

Immunoglobulin A Nephropathy IgAN

Interventions

  • DRUG Placebo
  • DRUG Ravulizumab

Study Locations (20)

California

  • Research Site - Loma Linda
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Orange
  • Research Site - San Diego
  • Research Site - San Francisco
  • Research Site - Stanford
  • Research Site - Torrance
  • Research Site - Valencia

Florida

  • Research Site - Bay Pines
  • Research Site - Miami
  • Research Site - Orlando

Georgia

  • Research Site - Acworth
  • Research Site - Atlanta
  • Research Site - Lawrenceville

Alabama

  • Research Site - Alabaster

Arizona

  • Research Site - Phoenix

Colorado

  • Research Site - Aurora

Iowa

  • Research Site - Iowa City

Trial Details

FieldValue
Enrollment Target 510 participants
Start Date 2024-03-29
Est. Completion 2030-07-19
Phase Phase 3

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06291376

The ClinicalTrials.gov registry entry for NCT06291376 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 265-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (92% higher). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06291376 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06291376 about?

NCT06291376 is a clinical study titled "Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)". The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

What is the current status of trial NCT06291376?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2024-03-29. Estimated completion is 2030-07-19.

What conditions does trial NCT06291376 study?

This clinical trial studies the following conditions: Immunoglobulin A Nephropathy, IgAN.

What interventions are being tested in trial NCT06291376?

The interventions under investigation include: Placebo (DRUG), Ravulizumab (DRUG).

Who is sponsoring clinical trial NCT06291376?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06291376 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Immunoglobulin A Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Immunoglobulin A Nephropathy

All registered trials for this condition

IgAN

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.